Salute e Benessere

Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply…

Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics, commented: "Satoreotide is the first Ac-225 labelled antagonist of the SSTR2 receptor targeting SCLC. The compound is scheduled to enter clinical development in the US as part of a transatlantic trial soon. The compound has demonstrated its potential as a Lutetium-177-labelled version in our ongoing Phase 1b clinical study in end stage-SCLC. Based on NorthStar's industry leadership and commercial expertise in cutting-edge…
PR Newswire
11/12/2024

Anticipated Rise in Collectibles Demand Starting 2024: The Collectibles Sector…

The collectibles industry, encompassing traditional and modern items, has experienced significant growth and transformation due to technological advancements, online industry marketplaces, and consumer behavior changes, encompassing a diverse range of items for personal interest and investment. The collectibles industry, encompassing traditional and modern items, has experienced significant growth and transformation due to technological advancements, online industry marketplaces, and consumer...
PR Newswire
11/12/2024

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in…

The Boston branch will serve as a crucial hub within Viva Biotech's global network, seamlessly connecting operations in China, the United States, the United Kingdom, Europe, and other regions. Together, these interconnected entities will form an efficient global operational system, poised to respond swiftly and precisely to the evolving landscape of drug discovery and development, as well as the increasingly diverse needs of our clients. TheBostonbranch will serve as a crucial hub within...
PR Newswire
11/12/2024

Crossject announces the pricing of its reserved capital increase and warrants…

Crossject to amend the Heights Capital Management, Inc. (“Heights”) bonds convertible in new shares or repayable Dijon, FRANCE, December 11, 2024 – 8 a.m. (CET)– Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, today announces the successful pricing of a reserved capital increase (the“Capital Increase” ) of...
Nasdaq GlobeNewswire
11/12/2024

Bavarian Nordic to Launch DKK 150 Million Share Buy-back Program

COPENHAGEN, Denmark, December 11, 2024– Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a share buy-back program of up to DKK 150 million in the first quarter of 2025. This decision should be viewed in the context of improved visibility around the Company's Travel Health business, driven by a number of completed and near-term expected events, including: A better-than-expected performance of the Travel Health business, as demonstrated by the recent guidance upgrade...
Nasdaq GlobeNewswire
11/12/2024

Syrebo Unveils Innovative Rehab Robots at MEDICA 2024: A Spectacular Showcase!

Syrebo has entered over 80 countries and 4000 medical units, serving more than 60,000 families. This year, its hand rehabilitation robot obtained patents in the US, Europe, and Japan. Syrebo will continue to provide high-quality products and services to promote the development of the rehabilitation industry. Syrebo has entered over 80 countries and 4000 medical units, serving more than 60,000 families. This year, its hand rehabilitation robot obtained patents in the US,Europe, andJapan...
PR Newswire
11/12/2024

Santhera Announces Approval from China's NMPA for AGAMREE® (Vamorolone) as a…

China's National Medical Products Administration (NMPA) approved AGAMREE® for the treatment of Duchenne muscular dystrophy inpatients aged 4 years and olderThis approval makes AGAMREE the first and only approved DMD therapy in ChinaPratteln, Switzerland, December 11, 2024 – Santhera Pharmaceuticals (SIX: SANN) announcesthat China's National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for use in China in patients aged 4 years and older. "DMD is a...
Nasdaq GlobeNewswire
11/12/2024

Pharming announces positive topline data in pediatric clinical trial of…

Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiencyData consistent with the improvements seen in the previously reported randomized controlled trial in adolescent and adult APDS patientsGlobal regulatory filings planned to begin in 2025 Leiden, the Netherlands, December 11, 2024:Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces positive...
Nasdaq GlobeNewswire
11/12/2024

BIOVAXYS ANNOUNCES REPRICING OF PRIVATE PLACEMENT OFFERING

The price per Unit has been reduced from $0.07 per Unit to $0.05 per Unit. As the Company's intention to raise $1,000,000 remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly. The price per Unit has been reduced from$0.07per Unit to$0.05per Unit. As the Company's intention to raise$1,000,000remains unchanged, the number of Units offered has increased from 14,285,715 Units to 20,000,000 Units accordingly. Each Unit...
PR Newswire
11/12/2024

Press Release: Two combination vaccine candidates for prevention of influenza…

Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the USFirst non-mRNA combination vaccine candidates that include two already licensed vaccines to prevent influenza and COVID-19 infectionsTwo phase 1/2 clinical studies are ongoing to evaluate the safety profile and immune response induced by the combination vaccine candidates Paris, December 11, 2024.The US Food and Drug Administration has granted Fast Track designation...
Nasdaq GlobeNewswire
11/12/2024

BSV has launched an awareness campaign "Voice of Africa" in the African…

A treatment developed over 50 years ago to prevent Rh disease—an often-fatal condition in foetuses and newborns—only reaches half of the women in the world who need it, according to a study led by researchers at Vagelos College of Physicians and Surgeons (VP&S) at Columbia University Irving Medical Centre*. Leading doctors appreciated the impact and effectiveness of this treatment but are concerned about its access and reach. A treatment developed over 50 years ago to prevent Rh…
PR Newswire
11/12/2024

TECNO Joins Forces with University of Leeds and Dar Al-Hekma University to…

Unveiled in 2023, TECNO's AI-powered Universal Tone technology is at the forefront of multi-skin tone mobile imaging innovation, authentically capturing the full spectrum of humanity's diversity, with a particular focus on emerging markets. This latest collaboration aims to expand the skin tone database of Saudi Arabia consumers, enhancing the Universal Tone algorithm to ensure TECNO devices provide more inclusive and accurate representations of the diverse skin tones found in Saudi Arabia. The…
PR Newswire
11/12/2024

Partnership Established to Advance WHO's Road Map for Neglected Tropical…

"This new partnership between GHIT and WHO represents a significant step forward in the fight against neglected tropical diseases," said Dr. Ibrahima Socé Fall, Director, WHO Global Neglected Tropical Diseases Programme. "By joining forces, we are not only accelerating research and development but also building sustainable frameworks and funding mechanisms needed to eliminate these diseases." "This new partnership between GHIT and WHO represents a significant step…
PR Newswire
11/12/2024

Global Veterinary Vaccines Market is Predicted to Cross USD 16 Billion by 2030 |…

Key Takeaways from the Veterinary Vaccines Market Report Key Takeaways from the Veterinary Vaccines Market Report To read more about the latest highlights related to the veterinary vaccines market, get a snapshot of the key highlights entailed in theGlobal Veterinary Vaccines Market Report Veterinary Vaccines Overview Veterinary vaccines are a cornerstone of animal healthcare, pivotal in preventing and controlling infectious diseases in domestic and wild animals. These...
PR Newswire
10/12/2024

Cellectis announces the drawdown of the third tranche of €5 million under the…

As a condition to the disbursement of Tranche C the Company issued 611,426 warrants to the benefit of the EIB, in accordance with the terms of the 14 thresolution of the shareholders' meeting held on June 28, 2024 and articles L. 228-91 and seq. of the French Commercial Code (the “Tranche C Warrants”).Each Tranche C Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of €1.70, corresponding to 99% of the volume-weighted average price of the Company's...
Nasdaq GlobeNewswire
10/12/2024

Medicover to evaluate a potential separate listing in India

If a listing takes place, the process is estimated to take 12-24 months. Updates on the evaluation will be provided in due course. If a listing takes place, the process is estimated to take 12-24 months. Updates on the evaluation will be provided in due course. For further information, please contact: Hanna Bjellquist, Head of Investor Relations+46 703 033 272 [email protected] This information is information that Medicover AB (publ)] is obliged to make public...
PR Newswire
10/12/2024

Crossject launches reserved capital increase and warrants issuance for an…

CROSSJECT INTENDS TO AMEND THE HEIGHTS CAPITAL MANAGEMENT, INC. (“HEIGHTS”) BONDS CONVERTIBLE INTO NEW SHARES OR REPAYABLE, UNDER CERTAIN CONDITIONS DIJON , FRANCE, December 10, 2024 – 7:15 p.m. (CET)– Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines harnessing its unique, award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations, has been in discussions with investors regarding a private...
Nasdaq GlobeNewswire
10/12/2024

CARBIOS announces the initiation of coverage of its stock by STIFEL

Clermont-Ferrand (France), Tuesday 10 December 2024 (6:00pm CET). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, today announces the initiation of coverage of its stock bySTIFELwith a study entitled “ rePETitive biorecycling ”.Carbios is also covered by the brokerage firms:Bryan, Garnier & CoExane BNP ParibasGilbert DupontKepler Cheuvreux...
Nasdaq GlobeNewswire
10/12/2024

Global Transient Protein Expression Market Size Set for Explosive Growth, With…

The transient protein expression market is segmented on the basis of product type, application, and end user. The report runs an in-depth analysis of market trends, key players, and future opportunities. The transient protein expression market is segmented on the basis of product type, application, and end user. The report runs an in-depth analysis of market trends, key players, and future opportunities. The report from The Insight Partners lists several stakeholders—including manufacturers,...
PR Newswire
10/12/2024

Genotyping Market Size Estimated to be Worth USD 154.35 Billion by 2031, at…

The List of Companies - Genotyping Market – The List of Companies - Genotyping Market – Request a Customized Copy of the Genotyping Market Report @https://www.theinsightpartners.com/reports/genotyping-market South and Central America [Brazil, Argentina, Rest of South and Central America] Middle East and Africa [South Africa, Saudi Arabia, UAE and Rest of Middle East and Africa] Get Sample Pages of Research analysis:...
PR Newswire
10/12/2024

Peptide Synthesis Market to Reach USD 1.12 Billion by 2031, Driven by…

Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=288496 Download PDF Brochure: https://www.marketresearchintellect.com/download-sample/?rid=288496 202 - Pages 126 – Tables 37 – Figures Scope Of The Report Peptide Synthesis Market Overview Market Definition and ScopeThe peptide synthesis market focuses on the production of peptides, which are short chains of amino acids used across pharmaceuticals, biotechnology, and...
PR Newswire
10/12/2024

Minimal Residual Disease Market to Hit USD 2.55 Billion by 2029 with 12.2% CAGR…

Browse in-depth TOC on "Minimal Residual Disease Market"268 - Tables48 - Figures245 - Pages Browse in-depth TOC on "Minimal Residual Disease Market" 268 - Tables 48 - Figures 245 - Pages A significant technological shift which could redefine the business landscape in the Minimal Residual Disease market, is the growing interest in developing and refining IGRA tests. IGRA presents more significant advantages than tuberculin skin tests because these are more accurate and…
PR Newswire
10/12/2024

Palestine Emerging coalition of Palestinian private sector leaders unveils…

As war continues, Healthcare Partnership & Transformation is a detailed and stress-tested plan for saving the Palestinian healthcare system which is overcome with debt, demand, and division. Led by Palestine Emerging, delivery of the plan is set to include Anera, the World Bank, the World Health Organisation, Gaza WASH Cluster members and a number of Palestinian private sector players from health and adjacent industries and private hospital networks. As war continues, Healthcare…
PR Newswire
10/12/2024

Pharmaceutical Manufacturing Equipment Market worth $26.94 billion in 2029 -…

Browse in-depth TOC on "Pharmaceutical Manufacturing Equipment Market" Browse in-depth TOC on "Pharmaceutical Manufacturing Equipment Market" 150 – Tables 70 – Figures 250 – Pages Pharmaceutical Manufacturing Equipment Market Report Scope: Mixing & blending machines segment is estimated to have the second largest market in the pharmaceutical manufacturing equipment market in 2023. The mixing and blending machines held the second greatest market share for...
PR Newswire
10/12/2024
Altri  Comunicati